NAD+: what it is, what it costs, and who sells it

NAD+ is a coenzyme present in every cell, central to energy metabolism and DNA repair — a real, well-established piece of basic cell biology, and the reason “boosting NAD+” is a coherent hypothesis rather than a fabricated one. A live DailyMed search for “NAD” (93 results) returns no FDA-approved NAD+ drug product of any kind — the results are Nadolol (an unrelated beta-blocker), homeopathic combination remedies, and over-the-counter cosmetic listings.

What actually gets sold under the NAD+ name splits into products with genuinely different evidence records: oral precursors (nicotinamide riboside, nicotinamide mononucleotide) that raise NAD+ indirectly, and injectable, IV, or nasal-spray NAD+ itself — the product the 125 sellers listed here overwhelmingly sell. Those two literatures are not interchangeable, and blending them is exactly what most marketing does.

A 2026 systematic review of 113 eligible studies (33 human, 80 rodent) evaluating NAD-related compounds found, in its own words: “No eligible outcomes trials evaluated intravenous or intramuscular NAD⁺ itself for anti-aging or wellness indications.” Zero. The one human pharmacokinetic pilot of directly infused NAD+ didn't even detect a plasma rise until after two hours of continuous infusion. Oral precursors are a different story: 28 randomized human trials consistently show they raise blood NAD+-related metabolites, though effects on functional outcomes are mixed — and that is a genuinely different, and commercially separate, product from what most of this board's rows sell. Read the full breakdown, route by route, in our NAD+ evidence review.

NAD+ is a naturally occurring coenzyme, not a novel synthetic peptide under FDA Pharmacy Compounding Advisory Committee (PCAC) review — unlike BPC-157, TB-500, and GHK-Cu, it does not appear on FDA's 2026 PCAC meeting agendas, because it sits in a different regulatory category rather than an earlier, unresolved stage of the same review. Two registered clinical trials confirm interest in the injectable form's basic tolerability is current, but both are explicitly framed around comparing subjective tolerability rather than testing whether it works — see our evidence review for both trial registrations.

A retrospective real-world tolerability study from a commercial IV-therapy chain found that patients receiving NAD+ IV reported moderate-to-severe gastrointestinal symptoms, increased heart rate, and chest pressure during infusions — a genuine, documented infusion-related safety concern that is specifically an infusion-rate issue, not a dosing-arithmetic one. That is also the direct, sourced reason this site runs no NAD+ reconstitution calculator: a generic vial/diluent/dose tool has no way to represent an infusion-rate concern responsibly. For the full safety and tolerability discussion, see our NAD+ evidence review. None of this is a recommendation for or against NAD+ — talk to a licensed clinician about your own situation.